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Abstract
Background: Small intestinal neuroendocrine tumors (SI-NETs) originate from the enterochromaffin cells in the
ileum and jejunum. The knowledge about genetic and epigenetic abnormalities is limited. Low mRNA expression
levels of actin gamma smooth muscle 2 (ACTG2) have been demonstrated in metastases relative to primary SI-NETs.
ACTG2 and microRNA-145 (miR-145) are aberrantly expressed in other cancers and ACTG2 can be induced by miR-
145. The aim of this study was to investigate the role of ACTG2 in small intestinal neuroendocrine tumorigenesis.
Methods: Protein expression was analyzed in SI-NETs (n = 24) and in enterochromaffin cells by
immunohistochemistry. The cell line CNDT2.5 was treated with the histone methyltransferase inhibitor 3-
deazaneplanocin A (DZNep), the selective EZH2 inhibitor EPZ-6438, or 5-aza-2’-deoxycytidine, a DNA
hypomethylating agent. Cells were transfected with ACTG2 expression plasmid or miR-145. Western blotting
analysis, quantitative RT-PCR, colony formation- and viability assays were performed. miR-145 expression levels were
measured in tumors.
Results: Eight primary tumors and two lymph node metastases displayed variable levels of positive staining.
Fourteen SI-NETs and normal enterochromaffin cells stained negatively. Overexpression of ACTG2 significantly
inhibited CNDT2.5 cell growth. Treatment with DZNep or transfection with miR-145 induced ACTG2 expression
(>10-fold), but no effects were detected after treatment with EPZ-6438 or 5-aza-2’-deoxycytidine. DZNep also
induced miR-145 expression. SI-NETs expressed relatively low levels of miR-145, with reduced expression in
metastases compared to primary tumors.
Conclusions: ACTG2 is expressed in a fraction of SI-NETs, can inhibit cell growth in vitro, and is positively regulated
by miR-145. Theoretical therapeutic strategies based on these results are discussed.
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Background
Small intestinal neuroendocrine tumors (SI-NETs) are
small, slow growing neoplasms that originate from the
enterochromaffin cells in the ileum and jejunum. These
rare tumors have an incidence about 1 case per 100 000.
Metastases have often already occurred at time of diag-
nosis and the 5-year survival rate is around 65 %. Due to
excess of tumor-secreted hormones; e.g. serotonin and
tachykinins, patients can suffer from the carcinoid syn-
drome, causing cutaneous flushing, diarrhea, carcinoid
heart disease and bronchoconstriction [1, 2]. The WHO
classification from 2010 divides small intestinal neuroen-
docrine neoplasms in three grades; G1-NETs (Ki67 <
3 %), G2-NETs (Ki67 3–20 %) and NEC (neuroendo-
crine carinomas, Ki67 > 20 %) [3]. SI-NETs (G1 and
G2) are most often resistant to chemotherapy and ra-
diation, and medical treatment is limited. Symptom
relief can be obtained by somatostatin-analogues and
interferon treatment. There is a great need of new
therapeutic options that could be beneficial to the
patients.
The knowledge of common genetic or epigenetic ab-
normalities is limited in SI-NETs. Loss of chromosome
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18 is most frequently seen, but no tumor-associated mu-
tations have been found on chromosome 18 [4–6]. A
putative role for TCEB3C (elongin A3), located at 18q21,
as tumor suppressor gene in SI-NETs was recently sug-
gested [7]. The mutation rate is overall low [8], and re-
cently, exome- and genome sequencing found CDKN1B
to be mutated in ~9 % of SI-NETs [9], implicating im-
portance for this gene in tumorigenesis.
We have previously observed expression of actin
gamma smooth muscle 2 (ACTG2) mRNA in a collec-
tion of primary SI-NETs, compared to undetectable ex-
pression levels in lymph node metastases [10]. Actin
proteins are involved in multiple intracellular processes,
including maintenance of the cytoskeleton and cell mo-
tility [11], and ACTG2 is normally found in enteric tis-
sue. Aberrant expression has been described in several
different cancer types and this can affect chemotherapy
sensitivity [12–14]. Lower expression levels of ACTG2
were detected in normal colon tissue compared to colon
carcinoma [15]. High expression levels of ACTG2 have
been associated with improved disease-specific survival
[16], and also with a more aggressive phenotype [17, 18].
Furthermore, microRNA-145 (miR-145) can positively
regulate expression of ACTG2 [19, 20], and overexpres-
sion of this microRNA inhibits cell proliferation, cell in-
vasion, tumor growth and can induce apoptosis in other
cancer cell types [19, 21].
The aim of this study was to investigate a possible role of
ACTG2 in small intestinal neuroendocrine tumorigenesis.
Methods
Tumor material and cell line
The patients included in the study (n = 28) were all di-
agnosed with SI-NET in the ileum and operated on at
Uppsala University Hospital. This study was approved by
the regional ethical review board in Uppsala (11-375/
1.1.2011, Local ethical vetting board in Uppsala (Regionala
etikprövningsnämnden i Uppsala)). Written informed
consent for participation and publication of individual
clinical details was obtained from all patients. All patients
were above 18 years of age at time of inclusion. Fifteen tu-
mors were classified as G1 NETs and 13 as G2 NETs.
Patient characteristics are summarized in Additional file 1:
Table S1. The tumors were snap frozen in liquid nitrogen
and kept at −70 °C.
A SI-NET cell line, CNDT2.5, developed from a liver me-
tastasis from a patient diagnosed with primary ileal SI-NET
[22], was used in the experiments. These cells expressed
neuroendocrine markers and somatostatin receptor 2 and
responded to synthetic somatostatin analogue (octreotide)
treatment [22, 23], although skepticism regarding the
neuroendocrine authenticity of this cell line has also been
raised [24]. The growth medium for CNDT2.5 was
DMEM-F12 complemented with 10 % fetal bovine serum
(Sigma Aldrich), 1 % vitamins, 1 % L-glutamine, 1 %
sodium pyruvate, 1 % nonessential amino acids and 1 %
PEST (penicillin-streptomycin), and the cells were cultured
at 37 °C in 5 % CO2.
Immunohistochemistry
Immunohistochemistry procedure is described in detail
in previous research [25, 26]. Paraffin embedded tumor
tissue (n = 24) sections (5 μm) were passed through de-
scending alcohol concentrations and distilled water.
Background staining was blocked with 3 % hydrogen
peroxide and heated in citrate buffer. The tissues were
treated with normal serum from goat (S-1000, Vector) and
two different rabbit polyclonal anti-ACTG2 antibodies
(NB100-91649 Novus Biologicals, diluted 1/200, and
TA313418 Origene, diluted 1/80) and anti-chromogranin A
antibodies (Ab-1, LK2H10, NeoMarkers, diluted 1/1000)
were used and incubated. A biotinylated secondary anti-
body from goat anti-rabbit (BA-100 Vector, diluted 1/200)
was added to the tissues and then treated with ABC com-
plex. Visualization was done with DAB color reagent. Ab-
sence of primary antibody was used as a negative control.
Consecutive sections from each tumor were incubated with
anti-ACTG2 and anti-chromogranin A antibody. Also,
consecutive sections of normal intestinal mucosa were
treated with anti-ACTG2 (NB100-91649 Novus Biologicals,
diluted 1/200) and anti-chromogranin A antibodies (Ab-1,
LK2H10, NeoMarkers, diluted 1/1000).
Immunofluorescence
Double immunofluorescence staining was done on sec-
tions of intestinal mucosa. Paraffin-embedded sections
were deparaffinized, hydrated and subjected to pre-
treatment (microwave heating for 10 min at 800 W,
followed by 20 min at 450 W in citrate buffer, pH 6.0).
The sections were blocked with normal goat serum (S-
1000, Vector) for 30 min before incubation with primary
antibody anti-chromogranin A (Ab-1, LK2H10, NeoMar-
kers, diluted 1/1000) for 90 min, followed by secondary
antibody Alexa Fluor 488 goat anti-mouse for 30 min.
Then, incubation with the next primary antibody anti-
ACTG2 (NB100-91649 Novus Biologicals), for 90 min,
was followed by the secondary antibody Alexa Fluor 594
goat anti-rabbit, for 30 min (Life Technologies). The sec-
tions were mounted with Vectashield with DAPI (Vector
Laboratories Inc.) and evaluated under light microscope.
Western blotting analysis
Proteins were extracted from tumors or CNDT2.5 cells
using Cytobuster™ protein extraction reagent (Novagen)
supplemented with Complete mini protease inhibitor cock-
tail tablets (Roche Diagnostics). Analysis of ACTG2 in
tumor tissue was done using a primary antibody; anti-actin
gamma2 (NB100-91649). Anti-Actin antibody (sc 1616,
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Santa Cruz) or coomassie blue was used as loading con-
trols, and for verification of transfection results a mouse
monoclonal anti-DDK antibody (TA50011, Origene) was
used. After incubation with the appropriate secondary anti-
body, bands were visualized using the enhanced chemilu-
minescence system (GE Healthcare).
Quantitative real-time RT-PCR
For extraction and purification of RNA, RNeasy Plus Mini
Kit (Qiagen) was used according to manufacturer’s instruc-
tions, and for microRNA, miRNeasy Mini Kit (Qiagen) was
used. Quantity was measured using NanoDrop. Reverse
transcription of DNA-free RNA with random hexamer
primers was performed using the “First strand cDNA
Synthesis kit” according to manufacturer’s instructions (Fer-
mentas) or MicroRNA RT kit (Life Technologies) using
10 ng RNA. Successful DNase I treatment of all RNA prep-
arations was established by PCR analysis of the MYC pro-
moter. qRT-PCR reactions were performed on the Step I
qRT-PCR system (Applied Biosystems) using TaqMan
Gene Expression Master Mix and assays for ACTG2
(Hs00242273_m1), GAPDH (Hs02758991_g1), hsa-miR-
145 (002278) and RNU48 (001006) (Applied Biosystems).
All samples were amplified in triplicates, and non-template
controls were included. Each sample’s mean threshold value
was corrected for the corresponding mean value for
GAPDH mRNA or RNU48 miRNA, used as endogenous
controls.
Drug treatment
CNDT2.5 cells were seeded onto 6 well plates and
treated with different concentrations of 5-aza-dC (5-aza-
2’-deoxycytidine, Sigma Chemical Co., St. Louis, MO,
USA, A3656) (0.025, 0.5, 1.0, 1.25, 1.5 μM) and DZNep
(3-deazaneplanocin A, 2.5, 5.0, 10.0, 12.5, 15 μM) and cell
viability was accessed using WST-1 (Roche Diagnostics
GmbH). Not toxic concentrations were chosen; 1 μM for
5-aza-dC and 10 μM DZNep. Freshly prepared 5-aza-dC
was used in the experiments. DZNep was kindly provided
by Dr. Victor Marques [27].
2 × 105 CNDT2.5 cells were seeded onto 6 well plates.
After 24 h 10 μM DZNep or 1 μM 5-aza-dC was added
in triplicates or 1, 2.5, or 5 μM EPZ-6438 (Selleckchem,
Houston, TX, USA), a specific EZH2 inhibitor [28], was
added to the wells and fresh medium and compounds
were added every 24 h. The cells were harvested after
72 h, 96 h for EPZ-6438 treated cells, for RNA prepara-
tions. The DZNep treatment was repeated three times
and 5-aza-dC and EPZ-6438 twice.
miR-145 analysis
CNDT2.5 cells (1 × 105) were distributed onto 6 well
plates. After 24 h hsa-miR-145 or negative control miR
(mirVana™miRNA mimics, Ambion) was transfected in
triplicates using 20 mM miRNA and 8 μl INTERFERin
siRNA transfection reagent (Polyplus Transfection). The
cells were harvested and RNA prepared after 72 h. Trans-
fections were repeated three times and successful transfec-
tion was determined by qRT-PCR using miR-145 assay.
Apoptosis was measured in transfected cells using the Cell
Death Detection ELISA kit (Roche Molecular Biochemi-
cals), and as a positive control cells were incubated
with 0.1 μg/ml Camptothecin (Sigma-Aldrich), a specific
inhibitor of DNA topoisomerase I that induces apoptosis.
Frozen tumor sections from 24 tumors; 8 primary tu-
mors, 9 lymph node metastases and 7 liver metastasis,
were when needed macro-dissected to obtain at least 80 %
tumor cells (in most cases more than 90 %) and RNA was
extracted using TriZol reagent (Invitrogen), according to
manufacturer’s instructions. cDNA synthesis followed by
qRT-PCR was performed as described above.
Proliferation and viability assays
A colony formation assay was performed and repeated
three times; CNDT2.5 cells (1 × 105) were seeded onto 6
well plates and transfected with 4 μg ACTG2-plasmid ex-
pression vector using 8 μl Lipofectamine 2000 reagent
(Life Technologies) according to manufacturer’s instruc-
tions. The ACTG2 expression vector consisted of an
expression-validated cDNA in pCMV6-Entry (TrueORF
Gold, catalog no. RC203151. Origene Technologies, Inc.,
Rockville, MD, USA) and empty pcDNA3.1 was used as
control. Six hours after transfection fresh medium was
added complemented with 1 % PEST and 0.2 mg/ml Ge-
neticin (G418, Sigma Aldrich). After 24 h 2000 cells were
distributed onto 6 well plates and fresh medium with
0.2 mg/ml Geneticin was added every 72 h. After 8 days
in selection the cells were fixed with 10 % acetic acid/10 %
methanol, stained with 0.4 % crystal violet, and visible col-
onies were photographed and counted. Successful trans-
fection was verified by western blotting after 24 h.
To analyze effect of ACTG2 on viability, CNDT2.5
cells were transiently transfected and 1000 cells were
seeded in a 96 well plate in triplicates. After 72 h cell
viability was measured using the cell proliferation re-
agent WST-1 (Roche Diagnostics GmbH) according to
manufacturer’s instructions.
Statistical analysis
All data are presented as arithmetical mean ± standard
deviation. Unpaired t test was used for statistical analysis
and p < 0.05 was considered significant.
Results
ACTG2 protein is variably expressed in 42 % of analyzed
SI-NETs
Protein expression was evaluated in 24 tumor sections
from 17 patients; 16 primary tumors and 8 lymph node
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metastases (Additional file 1: Table S1). Fourteen tumors
displayed no staining in the tumor cells (Fig. 1a) and six
tumors were positive in small areas of the section
(Fig. 1b). Furthermore, two tumors displayed larger areas
of positive staining and two tumors were weakly positive
in all of the tumor cells (Fig. 1c). No staining was de-
tected in absence of primary antibody (Fig. 1d). In total,
eight primary tumors and two lymph node metastases
(10 out of 24; 42 %) displayed positive staining for
ACTG2 in SI-NET cells (i.e. chromogranin-positive cells,
data not shown). Connective tissue showed mostly posi-
tive staining in 19 tumors (Fig. 1a), four displayed mostly
negative staining, and one tumor section lacked stromal
tissue. A different anti-ACTG2 antibody was used and
showed very similar results (data not shown). Western
blotting analysis for ACTG2 revealed one band in the
correct size range in two tumors with strong stromal
staining and not in two tumors that showed negative im-
munohistochemical staining (Fig. 1e). No obvious rela-
tions of ACTG2 expression to clinical data were
observed (not shown).
ACTG2 protein is not detected in enterochromaffin cells
of the normal small intestine
In order to determine whether ACTG2 is expressed in
chromogranin-positive cells of the normal intestinal mu-
cosa (enterochromaffin cells), immunohistochemistry on
consecutive tissue sections and also double immuno-
fluorescence were performed. Thorough analysis did not
reveal staining of both ACTG2 and chromogranin A in
the same cell (Fig. 2). Since these enterochromaffin cells
likely represent founder of SI-NET cells, our results
suggest that ACTG2 expression can be induced by un-
known mechanisms in a fraction of SI-NETs.
ACTG2 expression is induced by DZNep in vitro
We next wondered whether ACTG2 expression is con-
trolled by epigenetic mechanisms and whether it could be
induced by epigenetic drugs. Treatment of the human SI-
NET cell line CNDT2.5, with the global histone methyl-
transferase inhibitor 3-deazaneplanocin A (DZNep) but
not with the DNA hypomethylating agent 5-aza-2’-deoxy-
cytidine, induced relative ACTG2 mRNA expression ap-
proximately 20-fold (Fig. 3a; data not shown). However,
this gene induction did not seem to involve the histone
methyltransferase EZH2, which methylates histone 3 ly-
sine 27 and is inhibited by DZNep, since treatment with
the specific EZH2 inhibitor EPZ-6438 failed to induce
ACTG2 (Fig. 3b). Thus, ACTG2 expression can be con-
trolled directly or indirectly by mechanisms related to
DZNep treatment, but other than EZH2 repression. It
should be noted that positive controls for treatments with
5-aza-dC and EPZ-6438 were not included here.
Involvement of miR-145
Expression of ACTG2 is known to be positively regu-
lated by miR-145 in other cell types, and this was also
observed (~12-fold) in CNDT2.5 cells transiently trans-
fected by miR-145 (Fig. 4a). The level of miR-145 was
increased more than 1000-fold in transfected cells, as
determined by quantitative RT-PCR (data not shown).
Interestingly, the expression of miR-145 was induced by
DZNep treatment (~11-fold) (Fig. 4b). miR-145 is known










Fig. 1 Analysis of ACTG2 protein expression in SI-NETs by immunohistochemistry (a-d) using ACTG2 antibody (NB100-91649 Novus Biologicals)
and western blotting (e) using another ACTG2 antibody (TA313418 Origene). a Negatively stained tumor cells and strong stromal staining (20x). b
Areas with positively stained tumor cells, and negative stromal staining (20x). c Weak staining in all tumor cells (20x). d No staining in absence of
primary antibody (20x). e Western blotting analysis showing antibody specificity and correlation to immunohistochemistry analysis. One band only
was visualized in two tumors (lanes 2 and 3) displaying strong stromal staining, and no band was detected in two tumors (lanes 1 and 4) with no
staining in both tumor and stromal cells. Lane 1, lymph node metastasis; lanes 2–4, primary tumors. Coomassie blue staining was used as loading
control, ladder in kDa
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observed here (Fig. 4c). Relative miR-145 expression was
then determined in 24 SI-NETs; with a mean threshold
cycle (Ct)-value of 32.4 and somewhat higher expression
in 5 primary tumors compared to metastases and
CNDT2.5 cells. miR-145 was significantly less expressed
in liver metastases compared to primary tumors (Fig. 5a).
There was a tendency towards decreased expression in
lymph node metastases compared to primary tumors (p =
0.09). This needs to be examined in a larger cohort, al-
though in line with these results, previously published ex-
periments have shown significantly reduced expression of
ACTG2 mRNA in lymph node metastases compared to
primary tumors (Fig. 5b) [10].
Growth inhibition by ACTG2 in vitro
To investigate whether ACTG2 could control SI-NET
cell growth, a colony formation assay was performed on
CNDT2.5 cells stably transfected with an ACTG2 ex-
pression plasmid or empty vector. A significantly re-
duced ability to form colonies (by 32 %) compared to
control cells was observed (Fig. 6a and b). This finding
was supported by the reduced viability (Fig. 6c and d),
supporting a growth inhibitory effect of ACTG2 in vitro.
Discussion
ACTG2 is often aberrantly expressed in multiple cancers
[15, 17, 18], and low levels have been associated with
worse disease-specific survival [16]. Previously, low
mRNA expression levels of ACTG2 were demonstrated
in metastases relatively to primary SI-NETs [10]. To
investigate a possible role and function of ACTG2 in SI-
NET tumorigenesis this finding was first confirmed by
immunohistochemistry, demonstrating absence of pro-
tein expression in the majority of investigated SI-NETs.
Interestingly, eight primary tumors and two lymph node
metastases displayed positive staining for ACTG2 in
tumor cells, albeit at variable level and appearance. We
could not detect ACTG2 expression in the enterochro-
maffin cells of the normal intestinal mucosa, suggesting
that expression of ACTG2 can be induced at some point
during tumor progression representing a dedifferentiated
phenotype, rather than being normally expressed in this
cell type. Induction of ACTG2 at some point during pri-
mary tumor growth may have beneficial effects as
ACTG2 showed growth inhibitory effects, at least in
vitro. Expression of ACTG2 was detected in stromal cells
and whether ACTG2 can display growth effects here re-
mains to be investigated.
This study demonstrated that expression of ACTG2 can
be induced by DZNep treatment or miR-145 transfection
of the human SI-NET cell line CNDT2.5. Treatment with
DZNep also induced expression of miR-145, indicating a
possibility that induction of ACTG2 by DZNep may be
due to the effects on miR-145 expression. DZNep is a
Fig. 2 Double immunofluorescence staining of intestinal mucosa.
Chromogranin A is visualized as green, showing positively stained
enterochromaffin cells. ACTG2 is visualized as red and no staining is
detected in chromogranin A positive cells (yellow)
A B
Fig. 3 Effects on ACTG2 mRNA expression in CNDT2.5 cells after
DZNep (3-deazaneplanocin A) and 1.0 μM EPZ-6438 treatment,
a and b respectively
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potential drug in cancer treatment [29]. DZNep can in-
hibit the histone methyltransferase EZH2, which is the
catalytic subunit of polycomb repressive complex 2 and is
responsible for methylation of lysine 27 on histone 3, a re-
pressive mark [30]. A role of EZH2 was however excluded
here since EPZ-6438, a newly developed specific drug
inhibiting EZH2 enzymatic activity [28], was not able to
induce ACTG2 expression. MiR-145 is often deregulated
in cancer cells [31, 32] and is known to induce ACTG2 ex-
pression in breast cancer [19]. Here, it is demonstrated
that this occurs also in SI-NET cells; overexpression of
miR-145 increased expression of ACTG2 in vitro. There
was a decrease of miR-145 expression in metastasis com-
pared to primary tumors, as observed for ACTG2 [10].
Low levels of ACTG2 are correlated to chemotherapy re-
sistance [12, 14] and inducing this gene in SI-NETs would,
not only have a growth inhibitory effect, but also poten-
tially make the tumors more sensitive to treatment. SI-
NETs are difficult to cure due to their resistance to
chemotherapy and radiation, and new treatment strategies
are warranted. MicroRNAs are involved in gene regulation
and cancer development, and thus, have a potential role
as therapeutic targets. miR-145 has been suggested to be a
candidate for RNA medicine in colon tumors with a re-
duced expression [33]. miR-145 have multiple gene tar-
gets, and seems to be able to act as both a tumor
suppressor and an oncogene depending on tumor type.
Ruebel et al. [34] detected a difference in expression levels
A B C
Fig. 4 a Effects on ACTG2 mRNA expression in CNDT2.5 cells after miR-145 transfection. b Effects on miR-145 expression after DZNep treatment.
c Quantitative determination of cytoplasmic histone-associated-DNA-fragments (mono- and oligonucleosomes) after miR-145 transfection. Camptothecin















































Fig. 5 a miR-145 expression levels in 24 SI-NETs, and in CNDT2.5. A significant (p< 0.01) difference between primary tumors and liver metastases, and also
between lymph node and liver metastasis (p< 0.001) was observed. A tendency towards decreased expression in lymph node metastases compared to
primary tumors was detected (p= 0.09). b ACTG2 mRNA expression levels in 18 PT and 16 LNM. A significant (p< 0.01) difference between primary tumors
and lymph node metastases was observed. PT, primary tumor. LNM, lymph node metastasis. LM, liver metastasis
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of miR-145 between primary SI-NETs and metastases, and
here we confirmed a decrease in expression by tumor pro-
gression. These results suggest that miR-145 may be a
tumor suppressor and may be important for the ability to
metastasize. Inducing or introducing miR-145 may be a
potential new therapeutic strategy in SI-NETs.
Conclusions
Involvement of ACTG2 in small intestinal neuroendo-
crine tumorigenensis has not been investigated previ-
ously. Here, we demonstrate that ACTG2 protein
expression can be detected in a fraction of SI-NETs and
absent in others, and that it is regulated by miR-145.
Overexpression of ACTG2 inhibited cell growth and re-
duced cell viability in vitro. Further investigation is
needed to determine if introducing miR-145 in SI-NETs
could have therapeutic advantages.
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Fig. 6 a Colony formation assay in CNDT2.5 cells stably transfected with a plasmid expressing ACTG2 or with empty expression vector. b Western
blotting demonstrating successful transfection of the DDK epitope fused to ACTG2. c Viability assay using WST-1 after transient overexpression of
ACTG2. d Western blotting demonstrating successful transfection of the DDK epitope fused to ACTG2
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